2025-26 Hanmi Pharm ESG Report

ESG Management

Hanmi Pharm ESG Management

Hanmi Group ESG Decision-Making Structure

Hanmi Group is confident that ESG management is an essential element for sustainable management. Hanmi Group declares its commitment to sustainable management, focusing on climate change response, respect for human rights and strengthening labor rights, establishing safety and health without serious accidents, win-win cooperation, and ethical management.
In 2025, Hanmi Group newly established its ESG decision-making structure for future growth and sustainable management. In particular, the ESG Management Committee, centered around the CEOs of all group companies, will review ESG strategy formulation and ESG promotion tasks, and monitor performance. Matters discussed by the ESG Management Committee will be deliberated by the Board of Directors of each company, and strategies and policies will be decided to focus on the expansion and advancement of group-wide ESG management. In addition, the Board of Directors of Hanmi Pharmaceutical oversees company-wide ESG matters, including reporting ESG strategies and status, at least once a year.
The ESG Group, a dedicated ESG organization, comprehensively manages company-wide ESG management, including issue response, investment execution, disclosure, and evaluation, and reports ESG status and performance to the Board of Directors at least once a year. Moving forward, Hanmi Group plans to establish and operate an ESG working group to advance the ESG operations of its group companies.

Roles and Responsibilities

Category	Content
ESG Management Committee	ㆍDiscussion body among CEOs of Hanmi Group affiliates/related companies (once a year) ㆍDeliberation and decision-making on ESG-related board agenda items ㆍSetting ESG-related goals (KPIs) for each legal entity
ESG Team	ㆍGroup ESG Control Tower ㆍMonitoring of group-wide strategy execution/planning, etc. (e.g., managing ESG-related KPIs for related/affiliated companies)
ESG Working Council	ㆍRegular/ad-hoc operation led by the ESG Team ㆍSetting agenda items and sharing performance with the ESG Management Committee

Hanmi Group ESG Management Committee Operation Status

Category	Date	Key Agenda Items and Reporting Contents
ESG Management Committee	2025.09.18	ㆍReport on the establishment and operational plan of the ESG Management Committee

ESG Strategy

Hanmi Pharmaceutical establishes and continuously monitors the implementation status of strategies and plans from a mid-to-long-term perspective to systematically promote ESG management.
Under the Hanmi Group's "healthy Life, sustainable FUTURE"vision, we establish mid-to-long-term strategies for each ESG sector and diligently implement detailed strategic tasks according to the plans.

Hanmi Pharmaceutical ESG Management Roadmap

Establishment of ESG Management Foundation	Advancement of ESG Management		Expansion and Creation of ESG Management
PHASE 1	PHASE 2	PHASE 3	PHASE 4
2016~2018	2019~2022	2023~2025	2026~
Establishment of ESG Management Foundation · ESG Management Review/Diagnosis /Analysis · Reorganization of dedicated organization and decision-making structure · Derivation of mid-to-long-term tasks Publication of Sustainability Report	ESG Internalization Ⅰ · ESG KPI Development and Education Sector-specific Advancement Ⅰ · Strengthening Ethical Management, Safety and Health, Information Security · BCP/Human Rights Management System Improvement (Human Rights Due Diligence) · Establishment of Carbon Management System Ⅰ (Climate Change Response Roadmap, etc.)	ESG Internalization Ⅱ · Expansion of ESG Management across Group Companies Sector-specific Advancement Ⅱ · Supply Chain Management System Improvement & Expansion of Due Diligence · Establishment of Carbon Management System Ⅱ - Scope 3 Measurement - Climate Change Management System · Review and Reorganization of ESG Disclosure System	Full-scale Implementation of Carbon Neutrality Strategy Introduction of Renewable Energy Development of Carbon Neutrality Roadmap for Scope 3 Review of Eco-friendly Facility Introduction Expansion of Initiatives such as SBTi, RE100 Expansion of ESG Disclosure to all Group Companies

Status of Major ESG Task Implementation and UN SDGs in 2025

				Standard: Hanmi Pharm (Standalone)
Sector	Key Strategic goal	2025 Targets/ Performance		2026 Targets	UN SDGs
Carbon Neutrality	GHG	Targets	•SCOPE 1+2 emissions 71,810 tCO_2eq or less	•SCOPE 1+2 emissions 70,375 tCO_2eqor less*
		Performance	•SCOPE 1+2 emissions 68,426 tCO_2eq
	Energy	Targets	• Usage 1,386,914 GJ or less	• Energy usage 1,359,176 GJ or less
		Performance	• Usage 1,368,085 GJ
	Initiatives	Targets	• CDP response and B grade maintenance	• CDP response and B grade upgrade
		Performance	• CDP C grade
Environmental Impact Minimization	Pollutants	Targets	• Reduce emissions of major air/water pollutants by 30% compared to 2018 (Target emissions: 17 tons/12 tons or less)	• Reduce emissions of major air/water pollutants by 32% compared to 2018 (Target emissions: 16 tons/12 tons or less)
		Performance	ㆍMajor air/water pollutant emissions 2018 compared to, reduced by over 30% (emissions: 13 tons/11 tons)
	Water	Targets	ㆍWater intake reduced by 10% compared to 2018 (target intake: 701,381 tons or less) ㆍ Water reuse rate over 7.5%	ㆍWater intake reduced by 11% compared to 2018 (693,588 tons) ㆍWater reuse rate over 8%
		Performance	ㆍWater intake reduced by 36% compared to 2018 (intake: 501,352 tons) ㆍWater reuse rate over 9%
	Waste	Targets	ㆍGeneral/designated waste treated (633 tons/252 tons) or less ㆍWaste recycling rate over 72.5%	ㆍGeneral/designated waste treated reduced by 10% compared to 2018 (target treatment: 619 tons/246 tons) ㆍWaste recycling rate over 73%
		Performance	ㆍGeneral/designated waste treated reduced by 40% compared to 2018 (treatment: 387 tons/171 tons) ㆍ Waste recycling rate 80%
	Hazardous Chemicals	Targets	ㆍUsage reduced by 2% compared to the previous year	ㆍUsage reduced by 2% compared to the previous year
		Performance	ㆍUsage compared to previous year 46% reduction
Fostering an Eco-friendly Corporate Culture		Targets	ㆍHanmi Green Forest planted (over 1,000 trees) ㆍEco-friendly literature ratio over 90%/100% use of eco-friendly packaging boxes for produced medicines	ㆍHanmi Green Forest planted (over 1,000 trees) ㆍMaintain eco-friendly literature ratio over 80% ㆍ100% use of eco-friendly packaging boxes for produced medicines
		Performance	ㆍHanmi Green Forest 912 trees planted ㆍEco-friendly literature ratio 80% ㆍ100% use of eco-friendly packaging boxes for produced medicines
Proactive Safety and Health Activities		Targets	ㆍImprovement measures for aging facilities over 70% ㆍIntroduction of KRAS, JSA within online system	ㆍImprovement measures for aging facilities over 80% ㆍComprehensive survey of aging facilities from 2027 to 2030
		Performance	ㆍImprovement rate for aged facilities: 77% ㆍIntroduction of KRAS and JSA in online system
Advancement of Human Rights Management		Targets	ㆍHuman rights impact assessment and satisfaction survey for all employees ㆍUpdate of human rights impact assessment indicators	ㆍExpansion of human rights newsletter (2 times → 4 times)
		Performance	ㆍConduct human rights impact assessment/satisfaction survey for all employees ㆍHuman rights impact assessment indicators - Addition of divisional/business-specific indicators
Sustainable Supply Chain Management		Targets	ㆍIntroduction of online platform for supplychain due diligence ㆍExpansion of supply chain due diligence scope (40 entities in 2024)	ㆍCSDDD-based supply chain due diligence system reorganization ㆍSupply chain due diligence SOP revision ㆍMonitoring of identified improved suppliers
		Performance	ㆍIntroduction of online platform for supply chain due diligence and third-party due diligence ㆍExpansion of supply chain due diligence scope → 2025 level assessment (109)/in-depth assessment (36)
Compliance		Targets	ㆍIntroduction of third-party anonymous reporting channel	ㆍEstablishment of continuous legal monitoring system ㆍDissemination of CP standards and policies using AI
		Performance	ㆍIntroduction of third-party reporting channel K-Whistle
Strengthening Management System		Targets	ㆍMaintenance of 7 international certifications (ISO)	ㆍMaintenance of 7 international certifications (ISO)
		Performance	ㆍMaintenance of 7 international certifications (ISO)

* Hanmi Pharmaceutical's introduction of renewable energy was initially scheduled for gradual implementation starting in the first half of 2026.
However, due to contract schedules, its introduction is now planned for the second half of 2026 (Q4), leading to a readjustment of reduction targets.